This is a proposal to continue the development of radioiodinated tracers for mapping presynaptic nerve terminal density in mammalian brain. Parkinson s disease is characterized by massive degeneration of nigrostriatal dopamine neurons. Radiotracer imaging methods tend to underestimate actual nerve terminal loss possibly because of compensatory responses of surviving nerve terminals. A radiotracer that binds to surviving nerve terminals at a site minimally involved in homeostasis may provide a more precise assessment of nerve terminal loss. This capability would be especially important in tracking the long term efficacy of neuroprotective drug strategies initiated in patients with mild Parkinson s disease. Kilbourn and co-workers have developed a method for determining the regional brain density of the type 2 monoamine vesicular transporter (VMAT2) using [C-11]dihydrotetrabenazine (DTBZ). Studies with DTBZ have shown that striatal VMAT2 density is linearly correlated to the integrity of substantia nigra dopamine neurons and not subject to drug- or lesion-induced compensatory regulation. This proposal will focus on developing radioiodine labeled derivatives of DTBZ that selectively bind to VMAT2. A successful ligand will require simultaneous modification of two areas of the DTBZ molecule - one for iodine attachment and a second for polar group incorporation to counteract the lipophilicity-enhancing effect of iodine. Candidate iodo-DTBZ derivatives will be screened in vitro by radioligand binding assays using rat brain and bovine chromaffin vesicle ghosts. Ex vivo studies in rodents with [I-125]tracer will include determination of regional brain distribution by direct sampling/counting and by autoradiography. Tracer kinetic analysis with determination of brain and blood metabolites will be performed in rats. Validation of VMAT2 binding specificity will include testing for saturability, blockade by DTBZ and reserpine, stereoselectivity, and response to graded 6-hydroxydopamine striatal lesions. The most promising tracers will be labeled with iodine-123 and studied in baboons by emission tomography to test safety, imaging characteristics, and striatal washout time.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS025656-12
Application #
2873142
Study Section
Diagnostic Radiology Study Section (RNM)
Program Officer
Heetderks, William J
Project Start
1988-02-01
Project End
2001-01-31
Budget Start
1999-02-01
Budget End
2001-01-31
Support Year
12
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Mulholland, G K; Wieland, D M; Kilbourn, M R et al. (1998) [18F]fluoroethoxy-benzovesamicol, a PET radiotracer for the vesicular acetylcholine transporter and cholinergic synapses. Synapse 30:263-74
Van Dort, M E; Kim, J H; Tluczek, L et al. (1997) Synthesis of 11C-labeled desipramine and its metabolite 2-hydroxydesipramine: potential radiotracers for PET studies of the norepinephrine transporter. Nucl Med Biol 24:707-11
Jung, Y W; Frey, K A; Mulholland, G K et al. (1996) Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol. J Med Chem 39:3331-42
Van Dort, M E; Jung, Y W; Sherman, P S et al. (1995) Fluorine for hydroxy substitution in biogenic amines: asymmetric synthesis and biological evaluation of fluorine-18-labeled beta-fluorophenylalkylamines as model systems. J Med Chem 38:810-5
Gildersleeve, D L; Jung, Y W; Wieland, D M (1994) Direct optical resolution of vesamicol and a series of benzovesamicol analogues by high-performance liquid chromatography. J Chromatogr A 667:183-9
Kuhl, D E; Koeppe, R A; Fessler, J A et al. (1994) In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. J Nucl Med 35:405-10
del Rosario, R B; Jung, Y W; Baidoo, K E et al. (1994) Synthesis and in vivo evaluation of a 99m/99Tc-DADT-benzovesamicol: a potential marker for cholinergic neurons. Nucl Med Biol 21:197-203
Del Rosario, R B; Mangner, T J; Gildersleeve, D L et al. (1993) Synthesis of a nonpeptide carbon-11 labeled substance P antagonist for PET studies. Nucl Med Biol 20:545-7
Van Dort, M E; Jung, Y W; Gildersleeve, D L et al. (1993) Synthesis of the 123I- and 125I-labeled cholinergic nerve marker (-)-5-iodobenzovesamicol. Nucl Med Biol 20:929-37
Van Dort, M E; Kilbourn, M R; Chakraborty, P K et al. (1992) Iodine-125 and fluorine-18 labeled aryl-1,4-dialkylpiperazines: potential radiopharmaceuticals for in vivo study of the dopamine uptake system. Int J Rad Appl Instrum A 43:671-80

Showing the most recent 10 out of 14 publications